Forest Research Institute AZM-MD-302 Azimilide Shield 2
This is an event-driven randomized, multi-center, double-blind, placebo-controlled, parallel-group study of the safety and efficacy of a once-daily oral dose of 75 mg azimilide on the incidence of cardiovascular hospitalizations, cardiovascular emergency department visits, or cardiovascular deaths in patients with a transvenous ICD who have had a life-threatening ventricular arrhythmia. Patients are to be randomly assigned in a 1:1 ratio to receive daily oral doses of placebo or 75 mg of azimilide.
- At least 18 years of age with a left ventricular ejection fraction less than /=40% and have an implanted ICD
William Welch, M.D.
Karen D. Buchanan, RN, BSN
Clinical Research Nurse